121 related articles for article (PubMed ID: 19113954)
1. Edaravone derivatives containing NO-donor functions.
Chegaev K; Cena C; Giorgis M; Rolando B; Tosco P; Bertinaria M; Fruttero R; Carrupt PA; Gasco A
J Med Chem; 2009 Jan; 52(2):574-8. PubMed ID: 19113954
[TBL] [Abstract][Full Text] [Related]
2. Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs.
Rolando B; Filieri A; Chegaev K; Lazzarato L; Giorgis M; De Nardi C; Fruttero R; Martel S; Carrupt PA; Gasco A
Bioorg Med Chem; 2012 Jan; 20(2):841-50. PubMed ID: 22222158
[TBL] [Abstract][Full Text] [Related]
3. Effects of nitric oxide donor antioxidants containing the phenol vitamin E substructure and a furoxan moiety on ischemia/reperfusion injury.
Di Stilo A; Chegaev K; Lazzarato L; Fruttero R; Gasco A; Rastaldo R; Cappello S
Arzneimittelforschung; 2009; 59(3):111-6. PubMed ID: 19402340
[TBL] [Abstract][Full Text] [Related]
4. NO-donor melatonin derivatives: synthesis and in vitro pharmacological characterization.
Chegaev K; Lazzarato L; Rolando B; Marini E; Tosco P; Cena C; Fruttero R; Bertolini F; Reist M; Carrupt PA; Lucini V; Fraschini F; Gasco A
J Pineal Res; 2007 Apr; 42(4):371-85. PubMed ID: 17439554
[TBL] [Abstract][Full Text] [Related]
5. NO-donor phenols: a new class of products endowed with antioxidant and vasodilator properties.
Boschi D; Tron GC; Lazzarato L; Chegaev K; Cena C; Di Stilo A; Giorgis M; Bertinaria M; Fruttero R; Gasco A
J Med Chem; 2006 May; 49(10):2886-97. PubMed ID: 16686532
[TBL] [Abstract][Full Text] [Related]
6. Second generation of alpha-tocopherol analogs-nitric oxide donors: Synthesis, physicochemical, and biological characterization.
López GV; Blanco F; Hernández P; Ferreira A; Piro OE; Batthyány C; González M; Rubbo H; Cerecetto H
Bioorg Med Chem; 2007 Sep; 15(18):6262-72. PubMed ID: 17627828
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological characterization of potential antiatherogenic nitric oxide releasing tocopherol analogs.
López GV; Batthyány C; Blanco F; Botti H; Trostchansky A; Migliaro E; Radi R; González M; Cerecetto H; Rubbo H
Bioorg Med Chem; 2005 Oct; 13(20):5787-96. PubMed ID: 15993614
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide donor beta2-agonists: furoxan derivatives containing the fenoterol moiety and related furazans.
Buonsanti MF; Bertinaria M; Stilo AD; Cena C; Fruttero R; Gasco A
J Med Chem; 2007 Oct; 50(20):5003-11. PubMed ID: 17845020
[TBL] [Abstract][Full Text] [Related]
9. Novel antioxidant agents deriving from molecular combination of Vitamin C and NO-donor moieties.
Cena C; Chegaev K; Balbo S; Lazzarato L; Rolando B; Giorgis M; Marini E; Fruttero R; Gasco A
Bioorg Med Chem; 2008 May; 16(9):5199-206. PubMed ID: 18359636
[TBL] [Abstract][Full Text] [Related]
10. NO donors. Part 16: investigations on structure-activity relationships of organic mononitrates reveal 2-nitrooxyethylammoniumnitrate as a high potent vasodilator.
Koenig A; Roegler C; Lange K; Daiber A; Glusa E; Lehmann J
Bioorg Med Chem Lett; 2007 Nov; 17(21):5881-5. PubMed ID: 17855086
[TBL] [Abstract][Full Text] [Related]
11. The furoxan system: design of selective nitric oxide (NO) donor inhibitors of COX-2 endowed with anti-aggregatory and vasodilating activities.
Del Grosso E; Boschi D; Lazzarato L; Cena C; Di Stilo A; Fruttero R; Moro S; Gasco A
Chem Biodivers; 2005 Jul; 2(7):886-900. PubMed ID: 17193179
[TBL] [Abstract][Full Text] [Related]
12. Searching for new NO-donor aspirin-like molecules: a new class of nitrooxy-acyl derivatives of salicylic acid.
Lazzarato L; Donnola M; Rolando B; Marini E; Cena C; Coruzzi G; Guaita E; Morini G; Fruttero R; Gasco A; Biondi S; Ongini E
J Med Chem; 2008 Mar; 51(6):1894-903. PubMed ID: 18293898
[TBL] [Abstract][Full Text] [Related]
13. NO-glibenclamide derivatives: prototypes of a new class of nitric oxide-releasing anti-diabetic drugs.
Calderone V; Rapposelli S; Martelli A; Digiacomo M; Testai L; Torri S; Marchetti P; Breschi MC; Balsamo A
Bioorg Med Chem; 2009 Aug; 17(15):5426-32. PubMed ID: 19595600
[TBL] [Abstract][Full Text] [Related]
14. NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties.
Chegaev K; Lazzarato L; Tosco P; Cena C; Marini E; Rolando B; Carrupt PA; Fruttero R; Gasco A
J Med Chem; 2007 Apr; 50(7):1449-57. PubMed ID: 17335184
[TBL] [Abstract][Full Text] [Related]
15. Amphiphilic NO-donor antioxidants.
Chegaev K; Lazzarato L; Rolando B; Marini E; Lopez GV; Bertinaria M; Di Stilo A; Fruttero R; Gasco A
ChemMedChem; 2007 Feb; 2(2):234-40. PubMed ID: 17183594
[TBL] [Abstract][Full Text] [Related]
16. [Synthesis and vascular relaxing activity of arecoline derivatives coupled with nitric oxide donors].
Huang ST; Huang WL; Zhang HB
Yao Xue Xue Bao; 2006 Jan; 41(1):71-5. PubMed ID: 16683531
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, molecular properties prediction and anticancer, antioxidant evaluation of new edaravone derivatives.
Polkam N; Ramaswamy VR; Rayam P; Allaka TR; Anantaraju HS; Dharmarajan S; Perumal Y; Gandamalla D; Yellu NR; Balasubramanian S; Anireddy JS
Bioorg Med Chem Lett; 2016 May; 26(10):2562-2568. PubMed ID: 27055942
[TBL] [Abstract][Full Text] [Related]
18. Electrochemical, quantum-chemical and antioxidant properties of antipyrine and its derivatives.
Bashkatova NV; Korotkova EI; Karbainov YA; Yagovkin AY; Bakibaev AA
J Pharm Biomed Anal; 2005 Apr; 37(5):1143-7. PubMed ID: 15862698
[TBL] [Abstract][Full Text] [Related]
19. The novel antioxidant edaravone: from bench to bedside.
Watanabe T; Tahara M; Todo S
Cardiovasc Ther; 2008; 26(2):101-14. PubMed ID: 18485133
[TBL] [Abstract][Full Text] [Related]
20. Development of a new class of potential antiatherosclerosis agents: NO-donor antioxidants.
Cena C; Boschi D; Tron GC; Chegaev K; Lazzarato L; Di Stilo A; Aragno M; Fruttero R; Gasco A
Bioorg Med Chem Lett; 2004 Dec; 14(24):5971-4. PubMed ID: 15546710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
